First Dallas Securities Inc. Sells 600 Shares of Novo Nordisk A/S (NYSE:NVO)

First Dallas Securities Inc. cut its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 3.7% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 15,476 shares of the company’s stock after selling 600 shares during the period. First Dallas Securities Inc.’s holdings in Novo Nordisk A/S were worth $1,987,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Cravens & Co Advisors LLC increased its position in shares of Novo Nordisk A/S by 1.0% in the first quarter. Cravens & Co Advisors LLC now owns 8,250 shares of the company’s stock worth $1,059,000 after purchasing an additional 85 shares during the last quarter. U.S. Capital Wealth Advisors LLC increased its position in shares of Novo Nordisk A/S by 0.6% in the fourth quarter. U.S. Capital Wealth Advisors LLC now owns 15,421 shares of the company’s stock worth $1,595,000 after purchasing an additional 90 shares during the last quarter. Clarius Group LLC increased its position in shares of Novo Nordisk A/S by 0.5% in the fourth quarter. Clarius Group LLC now owns 18,505 shares of the company’s stock worth $1,914,000 after purchasing an additional 93 shares during the last quarter. Tradewinds Capital Management LLC increased its position in shares of Novo Nordisk A/S by 2.0% in the fourth quarter. Tradewinds Capital Management LLC now owns 4,955 shares of the company’s stock worth $513,000 after purchasing an additional 95 shares during the last quarter. Finally, Atlas Brown Inc. increased its position in shares of Novo Nordisk A/S by 2.5% in the first quarter. Atlas Brown Inc. now owns 3,823 shares of the company’s stock worth $491,000 after purchasing an additional 95 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms recently weighed in on NVO. BMO Capital Markets restated an “outperform” rating and issued a $163.00 price objective on shares of Novo Nordisk A/S in a research report on Tuesday. Argus increased their price target on shares of Novo Nordisk A/S from $125.00 to $160.00 and gave the company a “buy” rating in a research report on Monday, June 10th. The Goldman Sachs Group began coverage on shares of Novo Nordisk A/S in a research report on Thursday, May 30th. They set a “buy” rating and a $156.00 price target on the stock. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research report on Monday, June 17th. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $145.67.

Novo Nordisk A/S Trading Down 1.2 %

Shares of NYSE:NVO traded down $1.75 during trading on Friday, reaching $142.74. 2,757,544 shares of the company traded hands, compared to its average volume of 3,502,773. The firm has a market capitalization of $640.55 billion, a price-to-earnings ratio of 49.24, a P/E/G ratio of 1.44 and a beta of 0.41. Novo Nordisk A/S has a 52-week low of $75.56 and a 52-week high of $148.15. The company has a current ratio of 0.70, a quick ratio of 0.50 and a debt-to-equity ratio of 0.17. The business’s fifty day moving average is $135.00 and its 200-day moving average is $123.35.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Thursday, May 2nd. The company reported $0.83 earnings per share for the quarter, beating analysts’ consensus estimates of $0.77 by $0.06. The firm had revenue of $9.52 billion during the quarter, compared to analyst estimates of $9.23 billion. Novo Nordisk A/S had a return on equity of 91.70% and a net margin of 36.56%. As a group, analysts forecast that Novo Nordisk A/S will post 3.41 EPS for the current year.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.